OTCMKTS:SGIOY Shionogi & Co., Ltd. Unsponsored ADR Q2 2026 Earnings Results & Report $9.95 +0.09 (+0.86%) As of 11:10 AM Eastern Shionogi & Co., Ltd. Unsponsored ADR beat analyst earnings expectations but missed on revenue in its Q2 2026 results, released October 27, 2025. The company reported EPS of $0.18 versus the $0.1602 consensus estimate, while revenue of $740.85 million fell short of the $742.35 million estimate by $1.49 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateOctober 27, 2025TimeBefore Market Opens Shionogi & Co., Ltd. Unsponsored ADR EPS ResultsActual EPS$0.18Consensus EPS $0.1602Beat/MissBeat by +$0.0198One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersShionogi & Co., Ltd. Unsponsored ADR Revenue ResultsActual Revenue$740.85 millionExpected Revenue$742.35 millionBeat/MissMissed by -$1.49 millionYoY Revenue GrowthN/AUpcoming EarningsShionogi & Co., Ltd. Unsponsored ADR's next earnings date is estimated for Friday, January 29, 2027, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Shionogi & Co., Ltd. Unsponsored ADR Q2 2026 Earnings FAQ Did Shionogi & Co., Ltd. Unsponsored ADR beat earnings estimates for Q2 2026? Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) reported earnings of $0.18 per share for Q2 2026, beating the consensus estimate of $0.1602. The report was announced on Monday, October 27, 2025. What was Shionogi & Co., Ltd. Unsponsored ADR's revenue for Q2 2026? Shionogi & Co., Ltd. Unsponsored ADR reported revenue of $740.85 million for Q2 2026, against a consensus estimate of $742.35 million. When is Shionogi & Co., Ltd. Unsponsored ADR's next earnings date? Shionogi & Co., Ltd. Unsponsored ADR's next earnings date is estimated for Friday, January 29, 2027. MarketBeat tracks confirmed and estimated earnings dates for Shionogi & Co., Ltd. Unsponsored ADR on the company's earnings history page. Shionogi & Co., Ltd. Unsponsored ADR Earnings HeadlinesReviewing Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) and RYTHM (NASDAQ:RYM)November 9, 2026 | americanbankingnews.comSHIONOGI & CO LTDNovember 1, 2026 | finanznachrichten.deYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 16 at 1:00 AM | Behind the Markets (Ad)Shionogi & Co., Ltd. unsponsored ADR (SGIOY) Q2 earnings lag estimatesOctober 29, 2026 | msn.comShionogi & Co. (SGIOY) Upgraded to Buy: Here's What You Should KnowOctober 14, 2026 | msn.comAll You Need to Know About Shionogi & Co. (SGIOY) Rating Upgrade to BuyFebruary 4, 2026 | msn.comSee More Shionogi & Co., Ltd. Unsponsored ADR Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Shionogi & Co., Ltd. Unsponsored ADR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Shionogi & Co., Ltd. Unsponsored ADR and other key companies, straight to your email. Email Address About Shionogi & Co., Ltd. Unsponsored ADRShionogi & Co., Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker. The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova. Shionogi serves patients in Japan and international markets through its own operations and collaborations with other pharmaceutical companies. Its partnerships have supported the development and commercialization of medicines in areas including HIV treatment.View Shionogi & Co., Ltd. Unsponsored ADR ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles 3 Building-Materials Stocks Rallying While Homebuilders Struggle to Find BuyersMarketBeat Week in Review – 11/9 - 11/133 AI Hardware Leaders Are Raising Dividends, But Which Offers More Income?Nu Holdings Earnings Show a Compounder Priced Like a Brazil BetCould Big Buybacks Be the Next Catalyst for These 3 AI Stocks?Cerebras Q3 Results: How Much More Proof Does Wall Street Need?Sandisk's Sell-Off May Be Losing Steam, But the Biggest Risk Still Looms Upcoming Earnings Walt Disney (11/17/2026)Home Depot (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026)Palo Alto Networks (11/18/2026)NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.